
Vtv Therapeutics, a clinical-stage biopharmaceutical company, has announced a new company president and CEO, it reports in a press release.
Vtv Therapeutics, which developes orally administered treatments for type 1 diabetes and psoriasis, has announced that Stephen L. Holcombe, former company president and CEO, has retired. He is being replaced by Deepa Prasad, who joins shortly before the company initiates a crucial phase III trial with its leading candidate TTP399, which is a treatment for type 1 diabetes.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app